CLEAN : Panel de salud de EEUU respalda píldora anticovid de Merck

The video discusses the progress in authorizing the first oral COVID-19 treatment in the U.S. Experts recommend Merck's molnupiravir, already approved in the UK, which reduces hospitalizations and deaths by 30% in high-risk patients. The drug works by introducing mutations in the virus's genetic material, potentially offering resistance to variants. However, concerns about side effects, such as DNA damage, exist. The FDA noted these effects were insignificant in rat studies and may soon grant emergency use authorization.

What new insight or understanding did you gain from this video?